Endocrinopathies and cardiopathies in patients with Turner syndrome
- Authors: Zaidieva Y.Z.1, Balan V.E.1, Serebrennikova K.G.2
-
Affiliations:
- Moscow Regional Research Institute of Obstetrics and Gynecology
- Central Clinical Hospital, Russian Academy of Sciences
- Issue: No 2 (2020)
- Pages: 14-20
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248758
- DOI: https://doi.org/10.18565/aig.2020.2.14-20
- ID: 248758
Cite item
Abstract
Ovarian dysgenesis, stunting, and infertility are common characteristics ofTurner syndrome (TS). Endocrinopathies and cardiopathies are less common, but can cause signif icant complications and are a leading cause of death in patients with TS. The prevalence of endocrine abnormalities, including osteoporosis that occurs in almost 60% of patients, hypothyroidism (3.2%) and glucose metabolism disorders (that occur with a variable frequency) are related to the age group. Therapy with estrogens and growth hormones alone or in combination improves bone density in patients with TS. Autoimmune thyroiditis is associated with the X-isochromic phenotype in women with TS in the f irst and second decades of life. Type 2 diabetes mellitus developing due to Xp haploid gene def iciency and a latent autoimmune β-cell response occurs with higher frequency in TS patients in different age groups. The prevalence of cardiopathies in TS patients is 23%; the most common cardiovascular malformations are coarctation of the aorta and bicuspid aortic valve. The risks of cardiovascular events require ultrasound monitoring throughout a patient’s entire life, during pregnancy in particular. TS patients need interdisciplinary and long-term care. This paper provides an overview of endocrinopathies and cardiopathies in patients with TS.
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Yansiyat Z. Zaidieva
Moscow Regional Research Institute of Obstetrics and Gynecology
Email: 7726101@rambler.ru
MD, Professor, Head of the Department of Gynecological Endocrinology
Vera E. Balan
Moscow Regional Research Institute of Obstetrics and Gynecology
Email: balanmed@gmail.com
MD, professor, head of the outpatient department
Klara G. Serebrennikova
Central Clinical Hospital, Russian Academy of Sciences
Email: klaraserebrennikova@mail.ru
MD, professor, supervisor of obstetrics and gynecology
References
- Morgan T. Turner syndrome: diagnosis and management. Am Fam Physician. 2007; 76: 405-10. PMID: 17708142
- Faienza M.F., Ventura A., Colucci S. Bone fragility in Turner syndrome: mechanisms and prevention strategies. Front Endocrinol (Lausanne). 2016; 7: 34. doi: 10.3389/fendo.2016.00034
- Wilson C.A., Heinrichs C., L arm ore K.A., Craen M., Brown-Dawson J., Shaywitz S., Ross J., Klein K.O. Estradiol levels in girls with Turner’s syndrome compared to normal prepubertal girls as determined by an ultrasensitive assay. J Pediatr Endocrinol Metab. 2003; 16: 91-6. http://dx.doi.org/10.1515/ jpem.2003.16.1.91
- Hagen CP, Main K.M., Kjaergaard S., Juul A. FSH, LH, inhibin B and estradiol levels in Turner syndrome depend on age and karyotype: longitudinal study of 70 Turner girls with or without spontaneous puberty. Hum Reprod. 2010; 25: 3134-41. doi: 10.1093/humrep/deq291
- Sowinska-Przepiera E., Andrysiak-Mamos E., Chefotowski K., Adler G. Association between ER-a polymorphisms and bone mineral density in patients with Turner syndrome subjected to estroprogestagen treatment-a pilot study. J Bone Miner Metab. 2011; 29: 484-92. doi: 10.1007/s00774-010-0247-3
- Vanderschueren D., Venken K., Ophoff J., Bouillon R., Boonen S. Clinical Review: sex steroids and the periosteum-reconsidering the roles of androgens and estrogens in periosteal expansion. J Clin Endocrinol Metab. 2006; 91: 378-82. http://dx.doi.org/10.1210/jc.2005-1766
- Han T.S., Cadge B., Conway G.S. Hearing impairment and low bone mineral density increase the risk of bone fractures in women with Turner’s syndrome. Clin Endocrinol (Oxf). 2006; 65: 643-7. doi: 10.1111/j.1365-2265.2006.02643.x
- Suganuma N., Kawai H., Furuhashi M. Serum follicle-stimulating hormone level is a predictor of bone mineral density in patients with hormone replacement therapy. Arch Gynecol Obstet. 2004; 269: 192-5. doi: 10.1007/s00404-003-0532-7
- Sun L., Peng Y., Sharrow A.C., Iqbal J., Zhang Z., Papachristou D.J., Zaidi S., Zhu L.L. FSH directly regulates bone mass. Cell. 2006; 125: 247-60. doi: 10.1016/j.cell.2006.01.051
- Nakashima T., Hayashi M., Fukunaga T., Kurata K., Oh-Hora M., Feng J.Q., Bonewald L.F. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011; 17: 1231-4. doi: 10.1038/nm.2452.
- Iqbal J., Sun L., Kumar T.R., Blair H.C., Zaidi M. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci U S A. 2006; 103: 14925-30. doi: 10.1073/pnas.0606805103
- Balga R., Wetterwald A., Portenier J., Dolder S., Mueller C., Hofstetter W. Tumor necrosis factoralpha: Alternative role as an inhibitor of osteoclast formation in vitro. Bone. 2006; 39: 325-35. doi: 10.1016/j.bone.2006.02.056
- Faienza M.F., Brunetti G., Ventura A., Piacente L., Messina M.F., De Luca F. Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner’s Syndrome. Bone. 2015; 81: 228-36. doi: 10.1016/ j.bone.2015.07.021
- Cannon J.G., Kraj B., Sloan G. Follicle-stimulating hormone promotes RANK expression on human monocytes. Cytokine. 2011; 53: 141-7. doi: 10.1016/j. cyto.2010.11.011
- Cicognani A., Pirazzoli P., Nicoletti A., Baronio F., Conti V., Bonetti S. The SHOX gene: a new indication for GH treatment. J Endocrinol Invest. 2010; 33: 15-8. PMID: 21057180
- Bakalov V.K., Axelrod L., Baron J., Hanton L., Nelson L.M., Reynolds J.C. Selective reduction in cortical bone mineral density in turner syndrome independent of ovarian hormone deficiency. J Clin Endocrinol Metab. 2010; 88: 5717-22. doi: 10.1210/jc.2003-030913
- Frederiksen A.L., Hansen S., Brixen K., Frost M. Increased cortical area and thickness in the distal radius in subjects with SHOX-gene mutation. Bone. 2014; 69: 23-9. doi: 10.1016/j.bone.2014.09.001
- Soucek O., Zapletalova J., Zemkova D., Snajderova M., Novotna D., Hirschfeldova K., Plasilova I., Kolouskova S., Rocek M., Hlavka Z. Prepubertal girls with Turner syndrome and children with isolated SHOX deficiency have similar bone geometry at the radius. J Clin Endocrinol Metab. 2013; 98: E1:241-7. doi: 10.1210/jc.2013-1113.
- Soucek O., Lebl J., Zapletalova J., Novotna D., Plasilova I., Kolouskova S. Bone geometry and volumetric bone density at the radius in patients with isolated SHOX deficiency. Exp Clin Endocrinol Diabetes. 2013; 121: 109-14. doi: 10.1055/s-0032-1333260.
- Chiovato L., Larizza D., Bendinelli G., Tonacchera M., Marino M., Mammoli C., Lorini R., Severi F., Pinchera A. Autoimmune hypothyroidism and hyperthyroidism in patients with Turner’s syndrome. Eur J Endocrinol. 1996; 134: 568-75. doi: 10.1530/eje.0.1340568
- Bianchi I., Lleo A., Gershwin M.E., Invernizzi P. The X chromosome and immune associated genes. J Autoimmun. 2012; 38: J187-92. doi: 10.1016/j. jaut.2011.11.012.
- Cogni G., Chiovato L. An overview of the pathogenesis of thyroid autoimmunity. Hormones (Athens). 2013; 12(1):19-29. doi: 10.1007/BF03401283
- Wikiera B., Barg E., Konieczna A., Glab E., Noczynska A. The prevalence of thyro-peroxidase antibodies and thyroid function in Turner’s syndrome. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2006; 12: 190-4. PMID: 17020654
- Lichiardopol C., Mota M., Braicu D., Militaru C., Mixich F. Diabetes mellitus and Turner syndrome. Rom J Intern Med. 2007; 45: 299-304. PMID: 18333365
- Bakalov V.K., Cheng C., Zhou J., Bondy C.A. X-Chromosome gene dosage and the risk of diabetes in Turner syndrome. J Clin Endocrinol Metab. 2009; 94: 3289-96. doi: 10.1210/jc.2009-0384
- Zhao L., Guo M., Matsuoka T.A., Artner I., Jarrett H.W., Friedman D. The Islet beta cell-enriched MafA activator is a key regulator of insulin gene transcription. J Biol Chem. 2009; 280: 11887-94. doi: 10.1074/jbc.M409475200
- Dulac Y., Pienkowski C., Abadir S., Tauber M., Acar P. Cardiovascular abnormalities in Turner’s syndrome: What prevention? Arch Cardiovasc Dis. 2008; 101: 85-90. doi: 10.1016/j.acvd.2008.05.007.
- Sybert V.P. Cardiovascular malformations and complications in Turner syndrome. Pediatrics. 1998; 101(1): E11. doi: 10.1542/peds.101.1.e11
- Castelo-Branco C. Management of Turner syndrome in adult life and beyond. Maturitas. 2014; 79: 471-5. doi: 10.1016/j.maturitas.2014.08.011.
- Mortensen K.H., Hjerrild B.E., Stochholm K., Andersen N.H., Sorensen K.E., Lundorf E., Horlyck A., Pedersen E.M.Dilation of the ascending aorta in Turner syndrome - a prospective cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2011; 13: 24. doi: 10.1186/1532-429X-13-24.
- Martin L.J., Ramachandran V., Cripe L.H., Hinton R.B., Andelfinger G., Tabangin M., Shooner K., Keddache M., Benson D.W. Evidence in favor of linkage to human chromosomal regions 18q, 5q and 13q for bicuspid aortic valve and associated cardiovascular malformations. Hum Genet. 2007; 121: 275-84. https://doi.org/10.1007/s00439-006-0316-9
- McBride K.L., Riley M.F, Zender G.A., Fitzgerald-Butt S.M., Tow bin J.A., Belmont J.W., Cole S.E. NOTCH1 mutations in individuals with left ventricular outflow tract malformations reduce ligand-induced signaling. Hum Mol Genet. 2008; 17: 2886-93. doi: 10.1093/hmg/ddn187.
- O’Brien K.D. Epidemiology and genetics of calcific aortic valve disease. J Invest Med. 2007; 55(6): 284-91. doi: 10.2310/6650.2007.00010.
- Nigam V., Srivastava D. Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol. 2009; 47(6): 828-34. doi: 10.1016/j.yjmcc.2009.08.008.
- Foffa I., Ait AH L., Panesi P., Mariani M., Festa P., Botto N., Vecoli C., Andreassi M.G. Sequencing of NOTCH1, GATA5, TGFBR1 and TGFBR2 genes in familial cases of bicuspid aortic valve. Bmc Med Genet. 2013; 14: 44. doi: 10.1186/1471-2350-14-44.
- Wolff D.J., Van Dyke D.L., Powell C.M. Laboratory guideline for Turner syndrome. Genet Med. 2010; 12: 52-5. doi: 10.1097/GIM.0b013e3181c684b2.
- Haber H.P., Ranke M.B. Pelvic ultrasonography in Turner syndrome: standards for uterine and ovarian volume. J Ultrasound Med. 2009; 18: 271-6. doi: 10.7863/jum.1999.18.4.271
- Marin A., Weir-McCall J.R., Webb D.J., van Beek E.J.R., Mirsadraee S. Imaging of cardiovascular risk in patients with Turner’s syndrome. Clin Radiol. 2015; 70(8): 803-14. doi: 10.1016/j.crad.2015.03.009.
- Watts N.B., Bilezikian J.P., Camacho P.M., Greenspan S.L., Harris S.T., Hodgson S.F., Kleerekoper M., Luckey M.M., McClung M.R. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract. 2010; 16: 1016-19. https://doi.org/10.4158/EP.16.6.1016
- Bondy C.A. Care of girls and women with Turner Syndrome: A Guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2007; 92(1): 10-25. doi: 10.1210/jc.2006-1374
- Gravholt C.H., Andersen N.H., Conway G.S., Dekkers O.M., Geffner M.E., Woelfle J., Backeljauw P.F. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017; 177(3): G1-70. doi: 10.1530/EJE-17-0430.
- Stephure D.K.; The Canadian Growth Hormone Advisory Committee. Impact of Growth Hormone Supplementation on Adult Height in Turner Syndrome: Results of the Canadian Randomized Controlled Trial. J Clin Endocrinol Metab. 2005; 90(6): 3360-6. doi: 10.1210/ jc.2004-2187
- Baronio F., Mazzanti L., Girtler Y., Lupi F., Longhi S. The influence of GH treatment on glucose homeostasis in girls with turner syndrome: a 7-year study. J Clin Endocrinol Metab. 2017; 102(3): 878-83. doi: 10.1210/ jc.2016-3179.
- Chamberlain J.J., Rhine hart A. S., Shaefer C.J., Neuman A. Diagnosis and management of diabetes: synopsis of the 2016 American diabetes association standards of medical care in diabetes. Ann Intern Med. 2016; 164(8): 542-52. doi: 10.7326/M15-3016
- Gravholt C.H. Turner syndrome and the heart: cardiovascular complications and treatment strategies. Am J Cardiovasc Drugs. 2002; 2(6): 401-13. doi: 10.2165/00129784-200202060-00005
- Allybocus Z.A., Wang C., Shi Hr, Wu Qh.Endocrinopathies and cardiopathies in patients with Turner syndrome, Climacteric. 2018; 21(6): 536-41. doi: 10.1080/13697137.2018.1501674.
- Madriago E., Nguyen T., McFerson M., Larson E.V., Airhart N., Moller J.H., Silberbach M. Frequency and outcomes of cardiac operations and catheter interventions in turner Syndrome. Am J Cardiol. 2012; 110(4): 580-5. doi: 10.1016/j.amjcard.2012.04.036.
Supplementary files
![](/img/style/loading.gif)